LSDIF (Lucy Scientific Discovery) DeferredTaxAndRevenue: $0.00 Mil (As of Dec. 2023)


What is Lucy Scientific Discovery DeferredTaxAndRevenue?

Lucy Scientific Discovery LSDIF DeferredTaxAndRevenue is $0.00 Mil as of Dec. 2023.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Lucy Scientific Discovery's current deferred tax and revenue for the quarter that ended in Dec. 2023 was $0.00 Mil.

Lucy Scientific Discovery DeferredTaxAndRevenue Related Terms

Lucy Scientific Discovery DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Lucy Scientific Discovery's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lucy Scientific Discovery DeferredTaxAndRevenue Chart

Lucy Scientific Discovery Annual Data
Trend Jun21 Jun22 Jun23
DeferredTaxAndRevenue
0.00 0.00 0.00

Lucy Scientific Discovery Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of $0.00 Mil mean?
Lucy Scientific Discovery (LSDIF) has a DeferredTaxAndRevenue of $0.00 Mil as of Dec. 2023. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Lucy Scientific Discovery.
Is Lucy Scientific Discovery's DeferredTaxAndRevenue too high?
Lucy Scientific Discovery's current DeferredTaxAndRevenue is $0.00 Mil.
How does Lucy Scientific Discovery's DeferredTaxAndRevenue compare to INQD and ZTS?
Lucy Scientific Discovery's DeferredTaxAndRevenue of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Drug Manufacturers company?
A good DeferredTaxAndRevenue depends on the Drug Manufacturers industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Lucy Scientific Discovery. Lucy Scientific Discovery's current DeferredTaxAndRevenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lucy Scientific Discovery stock overvalued right now?
Lucy Scientific Discovery (LSDIF) has a current DeferredTaxAndRevenue of $0.00 Mil. The current DeferredTaxAndRevenue is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Lucy Scientific Discovery (LSDIF), the current DeferredTaxAndRevenue is $0.00 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lucy Scientific Discovery Business Description

Address 301-1321 Blanshard Street, Victoria, BC, CAN, V8W 0B6
Lucy Scientific Discovery Inc is an early-stage psychotropics contract manufacturing company focused on becoming the contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry. Its drug products are designed to treat a range of mental health and cognitive conditions.